Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncANIX · Entity 6698 | Director · Chief Executive Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 672,000 |
Reported balance
After 2026-09-24 transaction · row 1
1 source rowRow 1 · 2026-09-24 · Purchase · Acquired 7,000 · Balance 672,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 213,333 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 6 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,333 Underlying: Common Stock · 213,333 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 213,333 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 5 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 213,333 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 106,667 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 4 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,667 Underlying: Common Stock · 106,667 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 106,667 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,667 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 320,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested in 36 equal monthly installments beginning on October 31, 2012. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 320,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 320,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested in 36 equal monthly installments beginning on October 31, 2012. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 10:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $4.12 | $41,200.00 |
DisclosureSEC source: 0001513162-19-000206 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,000 Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 08:58 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 4,000 | $4.21 | $16,840.00 |
DisclosureSEC source: 0001513162-19-000114 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 Read SEC document |
| April 24, 2019 Filed Apr 24, 2019 13:44 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $4.27 | $42,700.00 |
DisclosureSEC source: 0001513162-19-000111 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Read SEC document |
| October 25, 2018 Filed Oct 25, 2018 12:42 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 11,000 | $3.90 | $42,900.00 |
DisclosureSEC source: 0001513162-18-000267 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 11:19 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 3,000 | $4.08 | $12,240.00 |
DisclosureSEC source: 0001513162-18-000235 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,000 Read SEC document |
| September 13, 2018 Filed Sep 13, 2018 12:49 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 4,112 | $3.96 | $16,283.52 |
DisclosureSEC source: 0001513162-18-000232 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.951 to $3.9646, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 09:54 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 3,000 | $3.84 | $11,520.00 |
DisclosureSEC source: 0001513162-18-000233 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Read SEC document |
| September 12, 2018 Filed Sep 12, 2018 19:13 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 4,480 | $3.99 | $17,875.20 |
DisclosureSEC source: 0001513162-18-000231 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,888 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.9886 to $3.993, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 08, 2018 Filed May 14, 2018 20:44 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 1,500,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001513162-18-000125 · primary_doc.xml · derivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2028-05-08 F3 · derivative.exercise_date: The option vests and becomes exercisable as follows: (i) 500,000 shares vest if during any 20 trading day period on or before May 31, 2021, the average closing stock price of the issuers common stock is at least $5.00, (ii) 500,000 shares vest if during any 20 trading day period on or before May 31, 2021, the average closing stock price of the issuers common stock is at least $7.00, and (iii) 500,000 shares vest if during any 20 trading day period on or before May 31, 2021, the average closing stock price of the issuers common stock is at least $8.00 Read SEC document |
| May 08, 2018 Filed May 14, 2018 20:44 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 600,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001513162-18-000125 · primary_doc.xml · derivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2028-05-08 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on a monthly basis over three years beginning on May 31, 2018. Read SEC document |
| May 08, 2018 Filed May 14, 2018 20:44 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantRestricted Stock Award · Derivative | 1,500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001513162-18-000125 · primary_doc.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The restricted stock award vests in its entirety if during any 20 trading day period on or before May 31, 2021 in which the reporting person is employed by the issuer, the average closing stock price of the issuers common stock is at least $11.00. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 200,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 10 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2026-02-18 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in 36 consecutive monthly installments beginning on March 31, 2016. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 200,000 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 9 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2026-02-18 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in 36 consecutive monthly installments beginning on March 31, 2016. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 8 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 7 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 213,333 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 6 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,333 Underlying: Common Stock · 213,333 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 213,333 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 5 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 213,333 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 106,667 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 4 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,667 Underlying: Common Stock · 106,667 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 106,667 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,667 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 320,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested in 36 equal monthly installments beginning on October 31, 2012. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:59 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 320,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000253 · primary_doc.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 320,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested in 36 equal monthly installments beginning on October 31, 2012. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 11:11 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 10,000 | $0.90 | $9,000.00 |
DisclosureSEC source: 0001513162-17-000184 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,408 Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 10:39 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 8,078 | $0.88 | $7,108.64 |
DisclosureSEC source: 0001513162-17-000182 · primary_doc.xml · nonDerivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,408 Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 10:39 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 1,422 | $0.87 | $1,237.14 |
DisclosureSEC source: 0001513162-17-000182 · primary_doc.xml · nonDerivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,330 Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 10:39 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 500 | $0.86 | $430.00 |
DisclosureSEC source: 0001513162-17-000182 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,908 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.